Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Infections

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Immune System Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Acquired Immunodeficiency Syndrome

HIV Infections

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Anti-Infective Agents

All Drugs and Chemicals

HIV Protease Inhibitors

Protease Inhibitors

Nelfinavir

Enzyme Inhibitors

Anti-HIV Agents

Anti-Retroviral Agents

Antiviral Agents

Nelfinavir given in combination with radical RT

Nelfinavir tablets BD 7 days per week from D-7 of starting radiotherapy until completion of radiotherapy on D47. 3 dose levels: 750 mg bd; 1000 mg bd; and 1250 mg bd.

nelfinavir

Total dose of 66 Gy delivered in 33 fractions (2.0 Gy/fraction) to the primary tumour plus a margin.

Radical Radiotherapy

Katherine Vallis

The aim of this clinical trial is to test whether the drug nelfinavir, which can increase the effectiveness of radiotherapy, can be given safely at the same time as a full dose of radiotherapy for lung cancer.

It is thought that one way that nelfinavir works is through causing changes in the blood vessels within tumours. The status of tumour blood vessels and the blood flow through them will be investigated during the trial using special imaging techniques. The dose of radiation used in this trial is greater than that used in previous trials with nelfinavir in other disease settings and the response of normal lung to the combination of nelfinavir plus radiation is unknown. Therefore, a low dose of nelfinavir will be given to the first few patients that participate and will be gradually increased in subsequent groups of patients provided that no worrying side effects are identified. There is a single report of serious side-effects in an AIDs patient who was treated with radiotherapy for lung cancer when he was also taking nelfinavir. However, in this case nelfinavir was taken at a dose 3-fold higher than the highest dose level to be tested in this trial. An important goal of this trial is to select the optimum dose of nelfinavir to be used in combination with lung radiotherapy, that can then be tested more extensively in future trials.

The radiotherapy treatment in this trial has been carefully designed to minimise the amount of healthy lung that receives radiation. Some specialised imaging techniques will be used during radiotherapy planning and delivery to help ensure that the lung cancer is targeted very precisely by radiation and that normal lung is avoided as much as possible.

One effect of nelfinavir is to interfere with the function of a particular protein in cells (called AKT). The degree to which this happens can be measured in cells from blood or tissue samples. Therefore, another aim of the study is to investigate AKT and related proteins, to check whether nelfinavir is having the predicted effect.

Radical Lung Radiotherapy Plus Nelfinavir

A Phase I Dose Escalation Study of the HIV Protease Inhibitor, Nelfinavir, Given Concomitantly With Radical Radiotherapy (RT) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

To establish the maximum tolerated dose of nelfinavir in combination with radical radiotherapy for patients with non-small cell lung cancer

To assess the safety profile of combined nelfinavir together with radiotherapy in patients with NSCLC.

To determine in-field radiotherapy treatment control rate at 3 and 12 months post treatment.

Oxford University Hospitals NHS Trust

QA Coordinator, Cancer Centre

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Radical Lung Radiotherapy Plus Nelfinavir	NCT01447589	Lung Cancer	nelfinavir Radical Radioth...	18 Years -	Oxford University Hospitals NHS Trust
Radical Lung Radiotherapy Plus Nelfinavir	NCT01447589	Lung Cancer	nelfinavir Radical Radioth...	18 Years -	Oxford University Hospitals NHS Trust

Spots Global Cancer Trial Database for radiosensitiser